Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix Manufacturing Solutions, Brussels South Update: Cyclotron Installation Complete

News,

Telix today announces that it has completed the installation of two new cyclotrons at Telix Manufacturing Solutions (TMS) in Brussels South, Belgium, facilitating the production of radioisotopes and patient doses…

Read more

First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients

Clinical, News,

Telix and Grand Pharma today announce that a first patient has been dosed in the Phase III ZIRCON-CP trial of TLX250-CDx positron emission tomography (PET) imaging of clear cell renal…

Read more

Telix to Add FAP-Targeting Candidates to Theranostic Pipeline

ASX, News,

Telix today announces it will expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), one of the most promising pan-cancer targets in nuclear medicine. Telix’s development program…

Read more

Attack on Stroma – Targeting Fibroblast Activation Protein (FAP) to destroy cancer’s defences

News,

Cancer is a complex disease. Its growth is influenced not only by the cancer cells themselves but by its surroundings, known as the tumour microenvironment (TME). Telix is exploring a…

Read more

Telix ADSs Commence Trading on Nasdaq

ASX, News,

Telix announces that its American Depository Shares (ADSs) have commenced trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol…

Read more

Telix and Eckert & Ziegler to Partner on Actinium-225 Production Technology

ASX, News,

Telix today announces that it has entered into a technology collaboration and licence agreement with Berlin-based Eckert & Ziegler SE (EZAG) for the use of EZAG’s cyclotron-based systems to produce…

Read more

Telix Welcomes CMS Decision to Improve Payments for Diagnostic Radiopharmaceuticals

ASX, News,

Telix today welcomes the announcement by the United States (U.S.) Centers for Medicare & Medicaid Services (CMS) that it will pay separately for specialised diagnostic radiopharmaceuticals for Medicare Fee for…

Read more

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster PET Imaging with Illuccix®

News,

Telix today announces a partnership with California-based Subtle Medical, Inc. (Subtle Medical) for artificial intelligence (AI)-powered positron emission tomography (PET) imaging with Telix’s commercial PSMA-PET product, Illuccix®…

Read more

FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

ASX, News,

Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent for the imaging of glioma….

Read more

Telix to Spin Off Rhine Pharma™ to Expand Global Access to Radiopharmaceuticals

Clinical, News,

Telix today announces the spin-off of Rhine Pharma, which has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, technetium-99m(99mTc) and…

Read more
1 … 6 7 8 9 10 … 46

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings